Inflammatory disease Archives

Medical anca associated vasculitis avacopan

News and Trends 1 Dec 2021

Targeted Drugs for Rare Autoimmune Disease Hit Regulatory Milestones

New, more targeted treatments are on the horizon for the rare autoimmune disease ANCA-associated vasculitis, with a nod towards European approval for a first-in-class drug and positive phase II results from a rival treatment. In November, the Swiss firm Vifor Fresenius Medical Care Renal Pharma (VFMCRP) received a thumbs-up from the EMA for avacopan, a […]

December 1, 2021 - 4 minutesmins - By Anita Chakraverty

Interview 10 May 2021

The Rollercoaster of Repurposing an Arthritis Drug for Covid-19

The Covid-19 pandemic created an opportunity for many biotech companies to repurpose their existing programs into vaccines and treatments for the novel coronavirus. Cyxone’s CEO Tara Heitner and COO Malin Berthold discuss how they approached this shift at their company. Cyxone was founded in 2015 to develop drugs for rheumatoid arthritis and multiple sclerosis. Based […]

May 10, 2021 - 8 minutesmins - By Larissa Warneck-Silvestrin

News and Trends 5 Oct 2020

Galapagos’ Arthritis Drug Approved in EU and Japan Amid US Rejection

The recent EU and Japan approvals of the rheumatoid arthritis drug filgotinib contrast with the FDA’s rejection in August. What does this signal for Galapagos, Gilead, and other biotechs working in inflammatory disease? For Galapagos and Gilead, it’s been a rollercoaster few months. In August, the FDA decided against approving their drug filgotinib for treating […]

October 5, 2020 - 5 minutesmins - By Jonathan Smith

News and Trends 25 Sep 2020

Roche Confirms Pharma Appetite for Inflammatory Disease Treatments

Roche’s acquisition of the Irish biotech Inflazome is a vote of confidence for emerging inflammatory disease drugs. How could other companies in the field benefit from this takeover? The inflammation process is essential for our survival, as it helps the body to clear up damage after injury. However, uncontrolled inflammation can also harm us, causing […]

September 25, 2020 - 4 minutesmins - By Jonathan Smith

News and Trends 9 Jul 2020

€18M to Fund First-in-Class Systemic Sclerosis Drug

One of the largest biotech placements in the Nordic countries this year will accelerate the development of a first-in-class drug for chronic inflammation conditions such as systemic sclerosis that lacks the cardiovascular risks of current medications such as aspirin. Swedish biotech Gesynta Pharma raised €18.2M (SEK 190M) in a placement supported by returning investor Industrifonden […]

July 9, 2020 - 2 minutesmins - By Victor Kotsev

News and Trends 6 Jun 2020

Boost For Inflammatory Disease Biotech NodThera With €49M Series B

The UK-US biotech NodThera has raised €48.7M in Series B funding to progress its drug candidate through clinical trials for the treatment of inflammatory conditions such as inflammatory bowel disease. This round follows an impressive €32M Series A that Nodthera carried out in 2018. Danish firm Novo Ventures, part of the investment arm of Novo […]

June 6, 2020 - 3 minutesmins - By Helen Albert

lupus autoimmune disease neutrophil citryll

More News! 26 Nov 2019

Rare Inflammatory Disease Drug Beats Immunosuppressants in Phase III

A small molecule drug developed by the US company ChemoCentryx and its Swiss partner Vifor Fresenius Medical Care Renal Pharma (VFMCRP) was more effective at treating a rare inflammatory vascular disease than current treatments in a phase III trial. The drug avacopan was trialed in 331 patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. This life-threatening condition […]

November 26, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 21 Oct 2019

Update: Abivax’s Ulcerative Colitis Drug Effective Long-Term

Update (21/10/2019): An extension of French biotech Abivax’s phase IIa trial shows its treatment for the inflammatory bowel disease ulcerative colitis has good efficacy after a year of treatment, with 75% of the screened patients remaining symptom-free. Of the 32 patients in the original phase IIa trial, 19 patients were treated with Abivax’s drug in […]

October 21, 2019 - 2 minutesmins - By Clara Rodríguez Fernández

More News! 12 Sep 2019

French Biotech to Develop Septic Shock Therapy with €39M Series B

The French company Inotrem has raised €39M to fund an immunotherapy for septic shock, an often deadly condition caused by infections in the bloodstream. Led by the Hong Kong investor Morningside Ventures, the Series B round will finance a phase IIb trial of Inotrem’s lead candidate drug nangibotide, expected to start in November this year. […]

September 12, 2019 - 3 minutesmins - By Jonathan Smith

Ose Immunotherapeutics bpifrance milestone bowel disease

News and Trends 27 Aug 2019

Swedish Ulcerative Colitis Treatment Makes Phase II Comeback

InDex Pharmaceuticals’ ulcerative colitis drug candidate has achieved positive phase IIb results, suggesting work to improve its dosage after a previous phase III failure was successful. The Swedish company tested different doses of the small molecule drug cobitolimod against a placebo in patients with the inflammatory bowel disease ulcerative colitis. The 213 patients in the […]

August 27, 2019 - 2 minutesmins - By Jonathan Smith

acute respiratory distress syndrome pantherna berlin inflammatory disease

Startup Scout 2 Aug 2019

This Biotech Uses Messenger RNA to Treat Lethal Lung Inflammation

Based close to Berlin, Germany, the biotech startup Pantherna Therapeutics is developing a messenger RNA drug to treat a life-threatening lung condition that requires mechanical ventilation. Mission: To develop a messenger RNA (mRNA) drug to treat acute respiratory distress syndrome, an inflammatory lung reaction that kills up to half of patients with the condition. Acute […]

August 2, 2019 - 4 minutesmins - By Jonathan Smith

atlantic healthcare pouchitis inflammatory bowel disease

More News! 1 Aug 2019

Atlantic Healthcare’s Inflammatory Bowel Disease RNA Drug Fails Phase III

Hopes of seeing an approved treatment for the inflammatory bowel condition pouchitis have been dashed as the UK company Atlantic Healthcare’s RNA drug has proved ineffective in a phase III trial. The trial tested Atlantic Healthcare’s RNA drug alicaforsen as a treatment for patients with pouchitis. Patients with this condition have their colon surgically replaced […]

August 1, 2019 - 2 minutesmins - By Jonathan Smith

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us